GLUE
insider transactionsMonte Rosa Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-18.8K
0 buy · 18.8K sell
Net value · 30d
-$367.3K
$0 in · $367.3K out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
6
0 buy · 18.8K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Chief Scientific Officer · 10b5-1
$0
3.0K sh
Own +1%
-
Sell·S
Chief Scientific Officer · 10b5-1
$57.0K
3.0K sh · $19.00
Own -4%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$18.4K
3.0K sh · $6.14
Own +4%
-
Exercise·M
Chief Operating Officer · 10b5-1
$0
2.2K sh
Own +7%
-
Sell·S
Chief Operating Officer · 10b5-1
$41.3K
2.2K sh · $19.00
Own -3%
-
Exercise·M
Chief Operating Officer · 10b5-1
$8.7K
2.2K sh · $3.98
Own +3%
-
Grant·A
Director
$0
25.8K sh
Own New
-
Grant·A
Director
$0
25.8K sh
Own New
-
Grant·A
Director
$0
25.8K sh
Own New
-
Grant·A
Director
$0
25.8K sh
Own New
-
Grant·A
Director
$0
25.8K sh
Own New
-
Sell·S
Markus Warmuth KEY
President & CEO · 10b5-1
$9.2K
468 sh · $19.73
Own -0%
-
Sell·S
Markus Warmuth KEY
President & CEO · 10b5-1
$97.0K
5.0K sh · $19.41
Own -1%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$0
6.0K sh
Own +3%
-
Sell·S
Chief Scientific Officer · 10b5-1
$119.2K
6.0K sh · $19.87
Own -8%
-
Exercise·M
Chief Scientific Officer · 10b5-1
$36.8K
6.0K sh · $6.14
Own +9%
-
Exercise·M
Chief Operating Officer · 10b5-1
$0
2.2K sh
Own +6%
-
Sell·S
Chief Operating Officer · 10b5-1
$43.5K
2.2K sh · $20.00
Own -3%
-
Exercise·M
Chief Operating Officer · 10b5-1
$8.7K
2.2K sh · $3.98
Own +3%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Sharon Townson 10b5-1 | Exercise M | 3.0K | $0 |
| Jun 17, 2026 | Sharon Townson 10b5-1 | Sell S | 3.0K | $57.0K |
| Jun 17, 2026 | Sharon Townson 10b5-1 | Exercise M | 3.0K | $18.4K |
| Jun 17, 2026 | Jennifer Champoux 10b5-1 | Exercise M | 2.2K | $0 |
| Jun 17, 2026 | Jennifer Champoux 10b5-1 | Sell S | 2.2K | $41.3K |
| Jun 17, 2026 | Jennifer Champoux 10b5-1 | Exercise M | 2.2K | $8.7K |
| Jun 11, 2026 | Jan Skvarka | Grant A | 25.8K | $0 |
| Jun 11, 2026 | Christine Siu | Grant A | 25.8K | $0 |
| Jun 11, 2026 | Andrew N Schiff | Grant A | 25.8K | $0 |
| Jun 11, 2026 | Anthony M. Manning | Grant A | 25.8K | $0 |
| Jun 11, 2026 | Eric A Hughes | Grant A | 25.8K | $0 |
| Jun 1, 2026 | Markus Warmuth KEY 10b5-1 | Sell S | 468 | $9.2K |
| Jun 1, 2026 | Markus Warmuth KEY 10b5-1 | Sell S | 5.0K | $97.0K |
| May 29, 2026 | Sharon Townson 10b5-1 | Exercise M | 6.0K | $0 |
| May 29, 2026 | Sharon Townson 10b5-1 | Sell S | 6.0K | $119.2K |
| May 29, 2026 | Sharon Townson 10b5-1 | Exercise M | 6.0K | $36.8K |
| May 27, 2026 | Jennifer Champoux 10b5-1 | Exercise M | 2.2K | $0 |
| May 27, 2026 | Jennifer Champoux 10b5-1 | Sell S | 2.2K | $43.5K |
| May 27, 2026 | Jennifer Champoux 10b5-1 | Exercise M | 2.2K | $8.7K |
About GLUE insider trading
This page tracks insider transactions for Monte Rosa Therapeutics, Inc. (GLUE) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.